KLOW Blend: Dosage, Benefits & Side Effects

Also known as: GHK-Cu + BPC-157 + TB-500 + KPV blend

By Peptide Assistant Editorial Team · · · 19 sources cited

Overview

KLOW Blend is a four-peptide vial that combines GHK-Cu, BPC-157, TB-500 and KPV: the GLOW blend with the anti-inflammatory tripeptide KPV added. It is sold for tissue repair, skin and inflammation. Each ingredient has its own research record, mostly in cells and animals, and none has controlled human evidence as an injection. The blend itself has not been studied: no clinical or animal study has tested these four peptides together. The amount of each peptide per vial varies by vendor, so check the label.

Mechanism of Action

KLOW Blend combines four peptides that have been studied separately. GHK-Cu is a copper-binding tripeptide found in human plasma. It stimulated collagen synthesis in fibroblast cultures and increased collagen, protein and glycosaminoglycans in rat wound chambers. BPC-157 is a 15-amino-acid peptide derived from a protein in gastric juice. In rat and cell studies it promoted tendon fibroblast outgrowth and migration and new blood vessel formation through VEGFR2 signaling. TB-500 is a synthetic, acetylated fragment (amino acids 17–23, LKKTETQ) of thymosin beta-4. This actin-binding region promoted endothelial cell migration and vessel sprouting in cell studies and dermal wound repair in aged mice; most other research was done with full-length thymosin beta-4, not the fragment. KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. In cell and mouse studies it entered cells through the PepT1 transporter and inhibited NF-κB signaling, lowering pro-inflammatory cytokines, and it does not appear to act through melanocortin receptors. The rationale for blending is that these actions (collagen production, blood vessel growth, cell migration and lower inflammatory signaling) are all part of tissue repair and might add up. That has not been tested for the four together. The one controlled study of BPC-157 combined with TB-500, in rat Achilles tendon repair (2026), found no added benefit over either peptide alone.

KLOW Blend Benefits: What the Research Shows

  • GHK-Cu: human evidence is topical only. In a randomized, placebo-controlled trial, GHK-Cu gel increased closure of diabetic plantar ulcers (98.5% versus 60.8% median area closure), while a randomized trial of a tripeptide-copper cream in 86 venous ulcer patients found no difference from placebo. No human study of injected GHK-Cu was found
  • BPC-157: a 2025 systematic review found 36 studies, 35 of them preclinical; in animals it improved tendon, ligament, muscle and bone healing. Human evidence is three small uncontrolled studies with 30 participants in total
  • TB-500: a synthetic peptide with the same seven-amino-acid sequence promoted dermal wound repair in aged mice about as well as full-length thymosin beta-4. All human trials used full-length thymosin beta-4, not TB-500
  • KPV: oral KPV reduced colitis in mice in two 2008 studies. KPV has no published human trial
  • The combination: no study has tested GHK-Cu, BPC-157, TB-500 and KPV together. The one controlled study of BPC-157 combined with TB-500, in rat Achilles tendon repair (2026), found no added benefit over either peptide alone

KLOW Blend Dosage

  • Vial contents: GHK-Cu, BPC-157, TB-500 and KPV (80 mg total is a common size). The split between the four varies by vendor, and the dose of each peptide depends on that split
  • Per vendor instructions — typically 0.5–1 mL subcutaneous injection daily or every other day
  • Cycle: 4–8 weeks for inflammatory conditions, reassess and repeat as needed
  • Can be dosed in the morning or evening — no specific timing requirements
  • Subcutaneous injection into abdominal area for systemic anti-inflammatory effects
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

KLOW Blend Side Effects & Safety

Known Side Effects

  • Side effects of the blend have not been studied in humans; the effects below come from user reports of the individual peptides
  • Injection site reactions: redness, mild stinging, occasional bruising
  • Mild skin flushing after injection, reported with GHK-Cu
  • Temporary fatigue, lightheadedness or mild nausea, reported with TB-500 and BPC-157
  • Headache reported occasionally during first week
  • Skin darkening is not expected from KPV, which lacks the pigment-inducing activity of alpha-MSH
  • Rare: allergic reaction to specific blend components — discontinue if rash develops
  • Theoretical concern: BPC-157 and TB-500 both promote new blood vessel growth in laboratory studies, which could in theory support an existing tumor; this has not been studied in people

Safety Profile

The blend has not been safety-tested, and none of its four ingredients has adequate human safety data as an injection. The FDA lists injectable GHK-Cu, BPC-157, the TB-500 fragment and KPV among bulk drug substances that may present significant safety risks in compounding. It cites possible immunogenicity for GHK-Cu and BPC-157, and says it has identified no human exposure data for the TB-500 fragment or for KPV by any route. BPC-157's human record is three small uncontrolled studies. BPC-157 and TB-500 are prohibited in sport at all times under the WADA Prohibited List. People with active cancer should avoid the blend as a precaution, because BPC-157 and TB-500 promote blood vessel growth in laboratory studies. Those with Wilson's disease or copper sensitivity should avoid it because of the GHK-Cu. Avoid during pregnancy and breastfeeding. Blends add a further unknown: the amount of each peptide per vial varies by vendor, so ask for a certificate of analysis (COA) that lists each ingredient. No drug interaction studies have been done.

What to Expect

This timeline comes from user reports; neither the blend nor KPV has been studied in humans. Week 1–2: Subtle reduction in systemic inflammation — improved joint comfort, reduced bloating if GI-focused. Some users report improved energy as inflammatory burden decreases. Weeks 3–4: More noticeable anti-inflammatory benefits. GI symptoms improve if present. General well-being improves. Weeks 5–8: Maximum anti-inflammatory benefits. Chronic pain and inflammation reduced. Gut healing progresses. Results typically persist for weeks after discontinuation.

Common Stacks

Storage & Handling

Follow vendor-specific instructions. Generally: store lyophilized at 2–8°C; reconstituted at 2–8°C, use within 3–4 weeks. Protect from light.

Pricing & Available Variants

$120price range
80mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
  2. The Prohibited List. World Anti-Doping Agency. 2026.
  3. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026.
  4. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025.
  5. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026.
  6. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011.
  7. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017.
  8. Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012.
  9. Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003.
  10. Philp D, Huff T, Gho YS, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003.
  11. Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg. 2026.
  12. Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994.
  13. Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992.
  14. Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993.
  15. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988.
  16. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
  17. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008.
  18. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003.
  19. Brzoska T, Luger TA, Maaser C, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008.

Related Peptides

Track KLOW Blend in Your Protocol

Log your KLOW Blend doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free